Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer | Zendy

Cat N. Bui | Zendy; Ken O’Day | Zendy; Scott C. Flanders | Zendy; Nina Oestreicher | Zendy; Peter Francis | Zendy; Linda M. Posta | Zendy; Breanna Popelar | Zendy; Hong Tang | Zendy; Mark Balk | Zendy

AI Assistant Blog Pricing

Open Access

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Author(s) -

Cat N. Bui,

Ken O’Day,

Scott C. Flanders,

Nina Oestreicher,

Peter Francis,

Linda M. Posta,

Breanna Popelar,

Hong Tang,

Mark Balk

Publication year - 2016

Publication title -

journal of managed care and specialty pharmacy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.126

H-Index - 63

eISSN - 2376-1032

pISSN - 2376-0540

DOI - 10.18553/jmcp.2016.22.2.163

Subject(s) - enzalutamide , medicine , prostate cancer , docetaxel , medicaid , oncology , cancer , health care , cancer registry , emergency medicine , family medicine , economic growth , androgen receptor , economics

Prostate cancer is expected to account for approximately one quarter of all new diagnoses of cancer in American men in 2015. The cost of prostate cancer care is expected to reach $15.1 billion by the year 2020, up from $11.9 billion in 2010. Given the high burden of prostate cancer, health care payers are interested in quantifying the potential budget impact of new therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog